» Articles » PMID: 39334996

Variation in Antibiotic Prescription in High-Risk Febrile Neutropenia in Portuguese Hospitals

Overview
Specialty Pharmacology
Date 2024 Sep 28
PMID 39334996
Authors
Affiliations
Soon will be listed here.
Abstract

Introduction: Febrile neutropenia (FN) is a potentially severe entity, particularly in hemato-oncologic patients who have higher incidence of colonization with multidrug-resistant bacteria. Discrepancies among guidelines contribute to divergence in antimicrobial practices. Our objective was to assess the variation of practices in antimicrobial therapy in high-risk FN among Portuguese hematologists.

Methods: We conducted a cross-sectional study through the implementation of an online survey, open to all clinical hematologists in the country. To characterize practice patterns regarding critical elements in FN management, three clinical vignettes were designed to describe typical situations where narrow-spectrum empiric antibiotics (vignette 1), short-course therapy (vignette 2) and de-escalation (vignette 3) could be performed. The remaining questions characterized clinical experience, department size, and differentiation and decision-making process regarding FN antibiotic therapy.

Results: The survey yielded 31 responses from 11 hospitals across four regions. All respondents opted for empiric narrow-spectrum antibiotics, 22.6% opted for short-course therapy (mostly senior specialists from larger settings) and 35.5% for de-escalation (mostly young specialists). Availability of an FN protocol seemed to favor both approaches. These findings should be complemented by qualitative assessments of barriers to best practices and should support the need for interventions to improve antibiotic use in febrile neutropenia.

References
1.
Rashidi A, Kaiser T, Graiziger C, Holtan S, Rehman T, Weisdorf D . Gut dysbiosis during antileukemia chemotherapy versus allogeneic hematopoietic cell transplantation. Cancer. 2019; 126(7):1434-1447. DOI: 10.1002/cncr.32641. View

2.
Verlinden A, Mikulska M, Knelange N, Averbuch D, Styczynski J . Current antimicrobial practice in febrile neutropenia across Europe and Asia: the EBMT Infectious Disease Working Party survey. Bone Marrow Transplant. 2020; 55(8):1588-1594. PMC: 7391284. DOI: 10.1038/s41409-020-0811-y. View

3.
Aguilar-Guisado M, Espigado I, Martin-Pena A, Gudiol C, Royo-Cebrecos C, Falantes J . Optimisation of empirical antimicrobial therapy in patients with haematological malignancies and febrile neutropenia (How Long study): an open-label, randomised, controlled phase 4 trial. Lancet Haematol. 2017; 4(12):e573-e583. DOI: 10.1016/S2352-3026(17)30211-9. View

4.
Klastersky J, de Naurois J, Rolston K, Rapoport B, Maschmeyer G, Aapro M . Management of febrile neutropaenia: ESMO Clinical Practice Guidelines. Ann Oncol. 2016; 27(suppl 5):v111-v118. DOI: 10.1093/annonc/mdw325. View

5.
Ly W, Brown E, Pedretti Z, Auten J, Wilson W . Evaluation of early de-escalation of empiric antimicrobial therapy in acute leukemia patients with febrile neutropenia at a large academic medical center. J Oncol Pharm Pract. 2021; 29(2):305-310. DOI: 10.1177/10781552211067776. View